Proteomic comparison between non‐purified cerebrospinal fluid and cerebrospinal fluid‐derived extracellular vesicles from patients with Alzheimer's, Parkinson's and Lewy body dementia
Abstract Dementia is a leading cause of death worldwide, with increasing prevalence as global life expectancy increases. The most common neurodegenerative disorders are Alzheimer's disease (AD), dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD). With this study, we too...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-12-01
|
| Series: | Journal of Extracellular Vesicles |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jev2.12383 |
| _version_ | 1797374947470868480 |
|---|---|
| author | Yael Hirschberg Natalia Valle‐Tamayo Oriol Dols‐Icardo Sebastiaan Engelborghs Bart Buelens Roosmarijn E. Vandenbroucke Yannick Vermeiren Kurt Boonen Inge Mertens |
| author_facet | Yael Hirschberg Natalia Valle‐Tamayo Oriol Dols‐Icardo Sebastiaan Engelborghs Bart Buelens Roosmarijn E. Vandenbroucke Yannick Vermeiren Kurt Boonen Inge Mertens |
| author_sort | Yael Hirschberg |
| collection | DOAJ |
| description | Abstract Dementia is a leading cause of death worldwide, with increasing prevalence as global life expectancy increases. The most common neurodegenerative disorders are Alzheimer's disease (AD), dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD). With this study, we took an in‐depth look at the proteome of the (non‐purified) cerebrospinal fluid (CSF) and the CSF‐derived extracellular vesicles (EVs) of AD, PD, PD‐MCI (Parkinson's disease with mild cognitive impairment), PDD and DLB patients analysed by label‐free mass spectrometry. This has led to the discovery of differentially expressed proteins that may be helpful for differential diagnosis. We observed a greater number of differentially expressed proteins in CSF‐derived EV samples (N = 276) compared to non‐purified CSF (N = 169), with minimal overlap between both datasets. This finding suggests that CSF‐derived EV samples may be more suitable for the discovery phase of a biomarker study, due to the removal of more abundant proteins, resulting in a narrower dynamic range. As disease‐specific markers, we selected a total of 39 biomarker candidates identified in non‐purified CSF, and 37 biomarker candidates across the different diseases under investigation in the CSF‐derived EV data. After further exploration and validation of these proteins, they can be used to further differentiate between the included dementias and may offer new avenues for research into more disease‐specific pharmacological therapeutics. |
| first_indexed | 2024-03-08T19:14:07Z |
| format | Article |
| id | doaj.art-fd1aaeeff9694aa29093821377144e73 |
| institution | Directory Open Access Journal |
| issn | 2001-3078 |
| language | English |
| last_indexed | 2024-03-08T19:14:07Z |
| publishDate | 2023-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Extracellular Vesicles |
| spelling | doaj.art-fd1aaeeff9694aa29093821377144e732023-12-27T09:15:41ZengWileyJournal of Extracellular Vesicles2001-30782023-12-011212n/an/a10.1002/jev2.12383Proteomic comparison between non‐purified cerebrospinal fluid and cerebrospinal fluid‐derived extracellular vesicles from patients with Alzheimer's, Parkinson's and Lewy body dementiaYael Hirschberg0Natalia Valle‐Tamayo1Oriol Dols‐Icardo2Sebastiaan Engelborghs3Bart Buelens4Roosmarijn E. Vandenbroucke5Yannick Vermeiren6Kurt Boonen7Inge Mertens8Health Unit Flemish Institute for Technological Research (VITO) Mol BelgiumDepartment of Neurology, Sant Pau Memory Unit, Sant Pau Biomedical Research Institute Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona Barcelona SpainDepartment of Neurology, Sant Pau Memory Unit, Sant Pau Biomedical Research Institute Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona Barcelona SpainDepartment of Neurology and Bru‐BRAIN Universitair Ziekenhuis Brussel and NEUR Research Group, Center for Neurosciences (C4N), Vrije Universiteit Brussel (VUB) Brussels BelgiumData Science Hub, Flemish Institute for Technological Research (VITO) Mol BelgiumVIB Center for Inflammation Research, VIB Ghent BelgiumFaculty of Medicine & Health Sciences, Translational Neurosciences University of Antwerp Antwerp BelgiumHealth Unit Flemish Institute for Technological Research (VITO) Mol BelgiumHealth Unit Flemish Institute for Technological Research (VITO) Mol BelgiumAbstract Dementia is a leading cause of death worldwide, with increasing prevalence as global life expectancy increases. The most common neurodegenerative disorders are Alzheimer's disease (AD), dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD). With this study, we took an in‐depth look at the proteome of the (non‐purified) cerebrospinal fluid (CSF) and the CSF‐derived extracellular vesicles (EVs) of AD, PD, PD‐MCI (Parkinson's disease with mild cognitive impairment), PDD and DLB patients analysed by label‐free mass spectrometry. This has led to the discovery of differentially expressed proteins that may be helpful for differential diagnosis. We observed a greater number of differentially expressed proteins in CSF‐derived EV samples (N = 276) compared to non‐purified CSF (N = 169), with minimal overlap between both datasets. This finding suggests that CSF‐derived EV samples may be more suitable for the discovery phase of a biomarker study, due to the removal of more abundant proteins, resulting in a narrower dynamic range. As disease‐specific markers, we selected a total of 39 biomarker candidates identified in non‐purified CSF, and 37 biomarker candidates across the different diseases under investigation in the CSF‐derived EV data. After further exploration and validation of these proteins, they can be used to further differentiate between the included dementias and may offer new avenues for research into more disease‐specific pharmacological therapeutics.https://doi.org/10.1002/jev2.12383biomarkerscerebrospinal fluiddementiaextracellular vesiclesmass spectrometryproteomics |
| spellingShingle | Yael Hirschberg Natalia Valle‐Tamayo Oriol Dols‐Icardo Sebastiaan Engelborghs Bart Buelens Roosmarijn E. Vandenbroucke Yannick Vermeiren Kurt Boonen Inge Mertens Proteomic comparison between non‐purified cerebrospinal fluid and cerebrospinal fluid‐derived extracellular vesicles from patients with Alzheimer's, Parkinson's and Lewy body dementia Journal of Extracellular Vesicles biomarkers cerebrospinal fluid dementia extracellular vesicles mass spectrometry proteomics |
| title | Proteomic comparison between non‐purified cerebrospinal fluid and cerebrospinal fluid‐derived extracellular vesicles from patients with Alzheimer's, Parkinson's and Lewy body dementia |
| title_full | Proteomic comparison between non‐purified cerebrospinal fluid and cerebrospinal fluid‐derived extracellular vesicles from patients with Alzheimer's, Parkinson's and Lewy body dementia |
| title_fullStr | Proteomic comparison between non‐purified cerebrospinal fluid and cerebrospinal fluid‐derived extracellular vesicles from patients with Alzheimer's, Parkinson's and Lewy body dementia |
| title_full_unstemmed | Proteomic comparison between non‐purified cerebrospinal fluid and cerebrospinal fluid‐derived extracellular vesicles from patients with Alzheimer's, Parkinson's and Lewy body dementia |
| title_short | Proteomic comparison between non‐purified cerebrospinal fluid and cerebrospinal fluid‐derived extracellular vesicles from patients with Alzheimer's, Parkinson's and Lewy body dementia |
| title_sort | proteomic comparison between non purified cerebrospinal fluid and cerebrospinal fluid derived extracellular vesicles from patients with alzheimer s parkinson s and lewy body dementia |
| topic | biomarkers cerebrospinal fluid dementia extracellular vesicles mass spectrometry proteomics |
| url | https://doi.org/10.1002/jev2.12383 |
| work_keys_str_mv | AT yaelhirschberg proteomiccomparisonbetweennonpurifiedcerebrospinalfluidandcerebrospinalfluidderivedextracellularvesiclesfrompatientswithalzheimersparkinsonsandlewybodydementia AT nataliavalletamayo proteomiccomparisonbetweennonpurifiedcerebrospinalfluidandcerebrospinalfluidderivedextracellularvesiclesfrompatientswithalzheimersparkinsonsandlewybodydementia AT orioldolsicardo proteomiccomparisonbetweennonpurifiedcerebrospinalfluidandcerebrospinalfluidderivedextracellularvesiclesfrompatientswithalzheimersparkinsonsandlewybodydementia AT sebastiaanengelborghs proteomiccomparisonbetweennonpurifiedcerebrospinalfluidandcerebrospinalfluidderivedextracellularvesiclesfrompatientswithalzheimersparkinsonsandlewybodydementia AT bartbuelens proteomiccomparisonbetweennonpurifiedcerebrospinalfluidandcerebrospinalfluidderivedextracellularvesiclesfrompatientswithalzheimersparkinsonsandlewybodydementia AT roosmarijnevandenbroucke proteomiccomparisonbetweennonpurifiedcerebrospinalfluidandcerebrospinalfluidderivedextracellularvesiclesfrompatientswithalzheimersparkinsonsandlewybodydementia AT yannickvermeiren proteomiccomparisonbetweennonpurifiedcerebrospinalfluidandcerebrospinalfluidderivedextracellularvesiclesfrompatientswithalzheimersparkinsonsandlewybodydementia AT kurtboonen proteomiccomparisonbetweennonpurifiedcerebrospinalfluidandcerebrospinalfluidderivedextracellularvesiclesfrompatientswithalzheimersparkinsonsandlewybodydementia AT ingemertens proteomiccomparisonbetweennonpurifiedcerebrospinalfluidandcerebrospinalfluidderivedextracellularvesiclesfrompatientswithalzheimersparkinsonsandlewybodydementia |